uniQure (QURE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
The 2026 Annual General Meeting will be held on June 10, 2026, in Amsterdam, with shareholders voting on key proposals affecting governance, compensation, capital structure, and corporate policy.
Shareholders can vote online, by phone, or by mail, and may attend in person if proper notice is given.
The Board recommends voting in favor of all proposals and for an annual advisory vote on executive compensation.
Proxy materials are available online, supporting sustainability and cost reduction.
Voting matters and shareholder proposals
Proposals include adoption of 2025 Dutch statutory annual accounts, discharge of Board liability, reappointment of three non-executive directors, Board authority to issue shares and exclude pre-emptive rights, share repurchase authorization, appointment of KPMG as auditor, advisory votes on executive compensation and its frequency, amendment of the 2014 Share Incentive Plan, and amendments to the Articles of Association regarding the large company regime, share capital, and federal forum selection.
Each proposal has specific voting thresholds, with most requiring a simple majority, while some (e.g., exclusion of pre-emptive rights) require a two-thirds majority if less than half of share capital is represented.
The Board recommends voting "FOR" all proposals and "ONE YEAR" for the frequency of say-on-pay votes.
Board of directors and corporate governance
The Board consists of one executive and seven non-executive directors, with staggered terms to ensure continuity.
Three non-executive directors are nominated for reappointment until 2029.
All non-executive director nominees have extensive industry experience and serve on key committees.
The Board structure supports long-term strategy and stability, with clear separation of CEO and Chair roles.
All directors except the CEO are considered independent under Nasdaq and SEC rules.
Latest events from uniQure
- Q1 2026 saw 125% revenue growth, $53.5M net loss, and regulatory and pipeline milestones.QURE
Q1 202611 May 2026 - Key votes include director reappointments, auditor selection, and amendments to governance and share capital.QURE
Proxy filing27 Apr 2026 - Shareholders will vote on director reappointments, compensation, auditor, and key governance changes.QURE
Proxy filing16 Apr 2026 - Huntington's therapy slowed progression in trials, but FDA seeks new phase III data.QURE
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - 2025 saw $16.1M revenue, strong cash, clinical progress, and ongoing regulatory hurdles.QURE
Q4 20252 Mar 2026 - AMT-130 achieved significant clinical milestones in Huntington's, supporting BLA submission plans.QURE
Corporate presentation3 Feb 2026 - AMT-130 slowed Huntington's disease progression by 80% and reduced neurodegeneration biomarkers.QURE
Study Update3 Feb 2026 - Gene therapy pipeline advances with regulatory focus and differentiated clinical programs.QURE
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Gene therapy pipeline advances with rapid clinical milestones and strong Huntington’s data.QURE
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026